IntegraGen announced today its unaudited business figures for the year 2020.

  • 2020 revenue amounted to 9.0 M € versus 8.1 M € in 2019, an increase of 10% over 12 months.
  • Increased sequencing services reported for company's Evry lab and at outsourced platforms run by the company for the SeqOIA project and at the Institut Pasteur.
  • Growth in sales also experienced with company's sequencing data interpretation software tools Mercury®, Sirius® and Galileo®
  • Company generated positive operating cash flow throughout the year and obtained a French State Guaranteed Loan (PGE) of € 1.8 million. The company's cash position improved from €2.8 million at the beginning of the year to €5.0 million at the end of December.

Click here to view press release

Attachments

  • Original document
  • Permalink

Disclaimer

IntegraGen SA published this content on 12 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2021 07:07:05 UTC